InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,892.81
(
0.38%
)
US TECH 100
20,024.40
(
0.81%
)
Dow Jones
43,432.61
(
-0.03%
)
Brent Oil
72.81
(
2.97%
)
Bitcoin
91,024.09
(
1.29%
)
Post# of 43481
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

pipette

Send PM Follow Ignore
Followers 2
Posts 52
Boards Moderated 0
Alias Born 06/27/2021

pipette

Re: None

Sunday, 10/03/2021 10:57:10 AM

Sunday, October 03, 2021 10:57:10 AM

Post# of 43481
Just read this in an article that I had not read anywhere else, any comments on this?
"Analysts have said clinical data do not differentiate lenzilumab, which would cost more than $10,000 per patient course of therapy, from tocilizumab (Actemra, Genentech Inc.), which gained an EUA in June and costs around $4,000."
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up